Sector Expert: Ed Arce

H.C. Wainwright & Co.

Image: Ed Arce

Ed Arce is a managing director in equity research and a senior analyst covering companies in the biopharmaceuticals and specialty pharmaceuticals sectors for H.C. Wainwright & Co. Previously, Arce was a senior research analyst with ROTH Capital Partners. Prior to ROTH, he covered biotechnology, biopharmaceutical, specialty pharmaceutical and select medical device companies as an analyst at MLV & Co. Prior to MLV, Arce covered the biotechnology sector at Wedbush Securities, and large-cap pharmaceuticals at UBS Securities. Arce started his equity research career in 2005 as a research associate at First Albany Capital, covering specialty and generic pharmaceutical companies. He holds a master of science degree in finance (MSF) degree from Boston College, as well as a master's degree in business administration and a bachelor's degree in civil engineering, both from Florida International University. Mr. Arce is a board-licensed professional engineer, and a Level III CFA candidate.

Recent Interviews

Minimizing Mistakes in a Volatile Biotech Market: H.C. Wainwright's Ed Arce (2/24/16)

Continuing stock market volatility is causing some investors to rethink their biotech investments. For generalists, in particular, choosing a winning company is almost a roll of the dice. In this interview with The Life Sciences Report, Ed Arce, a managing director with H.C. Wainwright & Co., shares insights investors can use to avoid mistakes when evaluating up-and-coming companies, and identifies some likely winners for 2016.

What Moves Biotech Stocks? Ed Arce Has Answers. (10/18/12)

Biotech stocks move on material news, which means clinical data, regulatory progress, new partnerships and big contracts with new customers. Analyst Ed Arce of MLV & Co. holds to these principles as he shares compelling biotech names in this exclusive interview with The Life Sciences Report.

Recent Quotes

"DRRX provided a 4Q16 earnings update and indicated that they are actively working towards commencing a Phase 2 trial with an oral formulation of DUR-928 for PSC."

— Ed Arce, H.C. Wainwright & Co. (3/15/17)
more >

"Anticipate the initiation of a Phase 2b trial in acute kidney injury, and especially a potentially positive Phase 2a readout in an undisclosed chronic cholestatic liver disease, both expected later this year, to attract investor attention and interest in the program and DRRX."

— Ed Arce, H.C. Wainwright & Co. (2/28/17)
more >

"Cost analysis on ACRX's Zalviso bolsters a price well above consensus."

— Ed Arce, ROTH Capital Partners (6/3/14)
more >

Due to permission requirements, not all quotes are shown.